aandoeningen met hartklep Aortic valve disease coronary artery disease
Conditions
Interventions
3.4.1 Collection and processing blood
The study population can be divided into three groups of 15 patients. This sub
population has a certain wash volume of the ATS (700 ml, 1000 ml and 1300 ml).
Th
Sponsors
Medisch Centrum Leeuwarden
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: The study population involves 45 patients undergoing on-pump CABG or/and AVR procedure in the MCL, where ATS has been used. Male or female patients aged 18 years or older who were in a non-emergency situation are eligible.
Exclusion criteria
Exclusion criteria: Exclusion criteria includes patients who were using anticoagulant medication prior to surgery, patients with preoperative known coagulation problems and liver problems (increased APTT/ALAT/ASAT values in Electronic Health Record (EHR)). Also, patients in which hypothermia (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this pilot study is to understand more about possible residual heparin concentration in the ATS product. In addition, the relationship between wash quantity and residual fraction of heparin will be examined. The primary outcome of this study is the residual heparin fraction in the ATS product. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters are the ROTEM values (coagulation management: INTEM, EXTEM, FIBTEM and HEPTEM), APTT values, ACT values, blood loss and blood transfusion. Study information will be obtained from each patient, represented in a form in the Appendix. | — |
Countries
Netherlands
Outcome results
None listed